In China, the pharmaceutical sales of sample hospitals have an increase trend due to the population growth, awareness of the importance of health care, and increased aging population. Among all drug sales, the share of anti-infectives in recent years has always been at the top of the list. Therefore, CRI predicts that in the next few years, the sales volume of Cefoperazone Sodium and Sulbactam Sodium will rise as the market expands.

According to the CRI’s market research, the sales of the Cefoperazone Sodium and Sulbactam Sodium in China have an accelerated growth from 2017 to 2019. The revenue in 2019 is approximately CNY 1.57 billion in 2020, though it dropped about 13.69% compared to 2019. The reason for the decline is due to COVID-19. The CAGR of the total sales from 2016 to 2020 is 6.24%. Therefore, CRI analyzes that as the epidemic situation improves, the overall sales in China are expected to have a recovery growth in 2021-2025. In addition, after the implementation of the “4 + 7” policy (a plan for the centralized procurement), the price of Cefoperazone Sodium and Sulbactam Sodium may decrease, which could lead the market to expand in the future.

Topics Covered:
-The impact of COVID-19 on China’s Cefoperazone Sodium and Sulbactam Sodium market
– Sales value and volume of China’s Cefoperazone Sodium and Sulbactam Sodium 2016-2020
– Competitive landscape of China’s Cefoperazone Sodium and Sulbactam Sodium market
– Prices of Cefoperazone Sodium and Sulbactam Sodium in China
– Prices of Cefoperazone Sodium and Sulbactam Sodium in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Cefoperazone Sodium and Sulbactam Sodium market
– Prospect of China’s Cefoperazone Sodium and Sulbactam Sodium market from 2021 to 2025

The post Investigation Report on Chinese Cefoperazone Sodium and Sulbactam Sodium Market 2021-2025 first appeared on CRI Report.